Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 2—February 2023
CME ACTIVITY - Synopsis

Crimean-Congo Hemorrhagic Fever, Spain, 2013–2021

Helena Miriam Lorenzo Juanes1, Cristina Carbonell1, Begoña Febrer Sendra, Amparo López-Bernus, Alberto Bahamonde, Alberto Orfao, Carmen Vieira Lista, María Sánchez Ledesma, Ana Isabel Negredo, Beatriz Rodríguez-Alonso, Beatriz Rey Bua, María Paz Sánchez-Seco, Juan Luis Muñoz Bellido, Antonio Muro, and Moncef Belhassen-GarcíaComments to Author 
Author affiliations: Universidad de Salamanca, Salamanca, Spain (H. Lorenzo-Juanes, C. Carbonell, B. Febrer-Sendra, A. López-Bernus, A. Orfao, C. Viera Lista, M. Sánchez Ledesma, B. Rodriguez Alonso, B. Rey Bua, J.L. Muñoz Bellido, A. Muro, M. Belhassen-Garcia); Instituto de Investigación Biomédica de Salamanca, Salamanca (H.M. Lorenzo Juanes, C. Carbonell, B. Febrer Sendra, A. López-Bernus, C. Vieira Lista, B. Rodriguez-Alonso, B. Rey Bua, M.P. Sánchez-Seco, A. Muro, M. Belhassen-Garcia); Hospital Universitario de Salamanca, Salamanca (H.M. Lorenzo Juanes, C. Carbonell, M. Sánchez Ledesma, B. Rodríguez-Alonso, B. Rey Bua); Hospital El Bierzo, Ponferrada, Spain (A. Bahamonde); Centro de Investigación del Cáncer, Salamanca (A. Orfao); Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain (A. Orfao); Centro Nacional de Microbiologiia, Majadahonda, Spain (A.I. Negredo, M.P. Sánchez-Seco); Red de Investigación Colaborativa en Enfermedades Tropicales, Madrid (A.I. Negredo, M.P. Sánchez-Seco, J.L. Muñoz Bellido); Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Madrid (A.I. Negredo, M.P. Sánchez-Seco)

Cite This Article

Introduction

CME Logo

Medscape CME ACTIVITY

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at https://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: January 23, 2023; Expiration date: January 23, 2024
Learning Objectives

Upon completion of this activity, participants will be able to:

  • Analyze the disease condition of Crimean-Congo hemorrhagic fever

  • Assess the epidemiology of Crimean-Congo hemorrhagic fever in the current study

  • Assess the clinical presentation of Crimean-Congo hemorrhagic fever in the current study

  • Distinguish the most common genotype of Crimean-Congo hemorrhagic fever in the current study

CME Editor

Dana C. Dolan, BS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Dana C. Dolan, BS, has disclosed no relevant financial relationships.

CME Author

Charles P. Vega, MD, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. Disclosure: Charles P. Vega, MD, has the following relevant financial relationships: consultant or advisor for GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Authors

Helena Miriam Lorenzo Juanes, PharmD, PhD Student; Cristina Carbonell, MD, PhD; Begoña Febrer Sendra, BSc, PhD Student; Amparo López-Bernus, MD, PhD; Alberto Bahamonde, MD, PhD; Alberto Orfao, MD, PhD; Carmen Viera Lista, BSc, PhD Student; María Sánchez Ledesma, MD, PhD; Ana Isabel Negredo, PhD; Beatriz Rodríguez Alonso, MD, PhD; Beatriz Rey Bua, MD; María Paz Sánchez Seco, PhD; Juan Luis Muñoz Bellido, MD, PhD; Antonio Muro, MD, PhD; Moncef Belhassen-García, MD, PhD.

Top

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a viral infectious disease for which distribution of the main vector, Hyalomma spp. ticks, is expanding. We analyzed all 10 cases of CCHF diagnosed in Spain during 2013–2021; case-patient median age was 56.5 years, and 7 were men. We identified CCHF virus genotypes III and V. Six case-patients acquired the infection in urban areas. Sixty percent of patients were infected in summer and 40% in spring. Two patients met criteria for hemophagocytic syndrome. Seven patients survived. The epidemiologic pattern of CCHF in Spain is based on occasional cases with an elevated mortality rate. Genotype III and, to a less extent also genotype V, CCHF circulates in humans in a common geographic area in Spain. Those data suggest that the expansion pathways are complex and may change over time. Physicians should remain alert to the possibility of new CCHF cases.

Crimean-Congo hemorrhagic fever (CCHF) is a tickborne viral disease caused by the CCHF virus (CCHFV), a negative single-stranded RNA virus of the genus Orthonairovirus in the Nairoviridae family (1). CCHF is considered an emerging infectious disease because of the expanding distribution of its main vector, ticks of the genus Hyalomma. Consequently, CCHF is listed by the World Health Organization as one of the top-priority diseases for research and development in public health emergency contexts (https://www.who.int/activities/prioritizingdiseases-for-research-and-development-in-emergency-contexts) (2).

The spectrum of clinical manifestations of CCHF ranges from subclinical illness (including fever, headache, malaise, myalgia, sore throat, dizziness, abdominal pain, nausea, vomiting, conjunctivitis, and photophobia) (3) to acute infection with hemorrhage, multiorgan failure, and death (4). Laboratory findings are frequently remarkable, including leukopenia, thrombocytopenia, and elevated liver transaminases in serum (5). Some studies have suggested the relevance of the innate immune system in limiting the spread of the virus, but the specific mechanisms leading to asymptomatic versus severe disease remain unknown.

In recent years, the epidemiology of CCHFV has changed; climate change has been identified as one of the factors driving the circulation of the virus. CCHFV has been identified in Africa, Asia, and Europe, in territories located south of the 50th North parallel, the area inhabited by its main vector (68). CCHFV has caused major outbreaks in eastern Europe (9). In turn, CCHF is considered endemic in areas of southwestern Europe.

Our group identified the first human cases in western Spain in summer 2013 (1013). In Spain, the CCHFV genotype identified from patients in 2016 and 2018 belonged to the African genotype III, the European genotype V, and the Asian genotype IV where the group Africa 4 is placed (10,12,13). A strong clinical suspicion is required to obtain fast and accurate diagnosis, initiate supportive treatment if needed, and activate biosafety measures to prevent nosocomial transmission (10). Herein, we report on the clinical and epidemiologic pattern and the genotype of the virus identified in all patients with CCHF investigated in Spain from 2013 through May 2022.

The Clinical Research Ethics Committee of Investigation with Drugs of the Hospital Universitario de Salamanca (Salamanca, Spain) approved the study protocol (CEIMC PI 91 09/2017). All procedures described were carried out in accordance with the ethical standards described in the Revised Declaration of Helsinki of 2013. All clinical and epidemiologic data were anonymized.

Methods

Study Type and Sample Collection

We retrospectively analyzed records of all patients that had been diagnosed of CCHF in Spain during 2013–2022. Five cases were identified after searching PubMed for literature published during 2016–May 2022. Four cases were identified at Hospital Universitario de Salamanca (Salamanca, Spain) in 2020–2021. Another case was identified at Hospital del Bierzo (Ponferrada, Spain) in June 2021. All epidemiologic, clinical, and analytical parameters were recorded according to a predefined clinical protocol. For all cases, diagnosis of CCHF was confirmed at the National Microbiology Center of the Instituto de Salud Carlos III (Madrid, Spain).

Phylogenetic Analysis

We aligned CCHFV sequences using ClustalW software (https://www.genome.jp/tools-bin/clustalw). We constructed the phylogenetic tree using a Tamura 3-parameter model based on sequences of the CCHFV small segment. We used the neighbor-joining method in MEGA X software version 10.2.5 (https://www.megasoftware.net) and based bootstrap confidence limits on 1,000 replicates.

Statistical Analyses

We used the SPSS Statistics 25.0 (https://www.ibm.com/spss) for all statistical analyses. We calculated median (range) and mean values and their SDs for continuous variables; we used frequencies for categorical variables.

Results

We extracted data for patients 1, 2, 3, 4, and 8 from published papers (1013). In turn, we conducted retrospective analysis on the medical records of all other patients with CCHF identified from Hospital Universitario de Salamanca and Hospital del Bierzo; we recorded demographic patient data, case history, symptoms, clinical signs, laboratory results, and outcomes for each patient (Table 1). Patient median age was 56.5 years (range 30–74 years); 7 were men and 3 women. Six patients had been infected in urban areas. The distribution of cases during the year was as follows: 1 case in April, 1 in May, 2 in June, 2 in July, and 4 in August (Figure 1).

Eight of the 10 patients reported tick bites (Table 2). The mean +SD time from the bite to the onset of symptoms was 5.1 + 3.4 days (range 2–12 days). The median duration between the onset of symptoms and hospital admission was 5.1 + 3.1 days (range 2–12 days). All case-patients had sought care for fever and exanthema with a mean duration of 5.2 + 1.64 days (Figure 2). Eight patients had muscle soreness; 4 patients had diarrhea, and 4 had vomiting, nausea, or both. Three case-patients (5, 6, and 9) underwent bone marrow biopsy; 2 of them, patients 5 and 9, had hemophagocytosis, which fulfilled the criteria for hemophagocytic syndrome (Figure 3). Ferritin serum level was elevated in 7 patients.

All patients received antimicrobial treatment with doxycycline while hospitalized. In addition, 5 patients received supportive treatment, 4 patients had taken treatment for bleeding, and 3 patients received ribavirin. None of those receiving antiviral treatment died; however, the sample size was small.

The mean +SD score on the Bakir prognostic scale (16) was 5.0 + 2.3. Seven patients survived with full recovery, whereas the other 3 died. Those 3 patients who died had the highest scores on the Bakir scale (1 patient scored 8 and the other 2 scored 7).

In most cases (patients 1, 2, 5, 6, and 7), disease was caused by CCHFV genotype III (Africa 3). Patient 3 had a new lineage, Africa 4 (Figure 1) within genotype IV. Isolates from patients 4 and 9 belonged to genotype V (Europe 1). We did not identify the genotype for patients 8 and 10. Of note, genotypes III and V were found to circulate in the same geographic area. We deposited the sequences into GenBank under accession nos. KY492290 (patient 1), KY492289 (patient 2), MN689739 (patient 3), ON227355 (patient 4), OP776634 (patient 5), OP776632 (patient 6), OP776631 (patient 7), and OP776633 (patient 9).

Discussion

We describe the demographic, epidemiologic, clinical, and laboratory features of all 10 cases of CCHFV reported in Spain since 2013, when the causative agent was first discovered in this country (11). Our findings have updated the knowledge of CCHFV in Spain to show the pattern during the period 2013–2021 in southern Europe. Half (5/10) of the cases we described in this article were treated at Hospital Universitario de Salamanca (1013). CCHFV was found in western Spain in 2010 in ticks (Hyalomma lusitanicum) feeding on wild animals in the province of Caceres (17).

Studies carried out in the same period and the same geographic areas in Spain in healthy donors (18) showed a serologic prevalence of past infection of ≈1.16% and in patients who sought emergency care for febrile syndrome (13) of ≈2.22%. Altogether, these results suggest that CCHF is underdiagnosed in this region. However, the high frequency of asymptomatic patients, which exceeds 88% in some studies, might also account for such differences (3,4).

Spain’s geographic proximity to Africa is a risk factor for continuous entry of CCHFV. Its favorable climate, the wide presence of the vector involved in transmission, the variety of vertebrate animals that can act as amplifying hosts, and its location along the path of transit for migratory birds from CCHFV-endemic areas all increase the risk for spread of the virus.

Most infections in this study occurred in spring and summer in rural areas of central-western Spain. Of the cases that occurred in the southern part of the autonomous community of Castile and León, likely causes are specific climatic features (e.g., temperature, humidity), geographic conditions, flora and wildlife, the animal husbandry sector, and increased contact with animals and ticks. In this regard, field studies have confirmed that these areas are at risk for CCHF because of the abundance of H. lusitanicum ticks, the presence of CCHFV in the specimens collected, together with the high prevalence observed in wild and domestic animals in these and other areas of the country (17,1922).

The epidemiologic pattern we report for Spain resembles that of countries such as Greece and Kosovo (23,25), with few and occasional cases, and clearly differs from the epidemiologic evolution of countries such as Turkey (25), which has a marked and progressive increase in cases since its earliest recorded case in 2002. Those distinct epidemiologic evolution profiles might be related to differences in farming and sheepherding activities, as well as the specific climate conditions; in Turkey, a notable and specific risk factor is living at altitudes >836.5 m (26). We noted the possibility of secondary transmission of CCHF to healthcare workers, particularly during accidental contact such as resuscitation of severely ill patients, and the need for strict rules and protocol for handling potential secondary cases (10).

Clinical findings in the patients we reviewed revealed that the most common symptoms were fever, exanthema, and myalgia. However, we also noted findings of bleeding (7/10 cases) at higher frequencies than those reported previously (25). Two patients with CCHFV experienced hemophagocytic syndrome with hemophagocytosis in the bone marrow. Hemophagocytic syndrome is a rare and severe disease characterized by fever; hepatosplenomegaly; cytopenia; elevated ferritin, lactate dehydrogenase and triglyceride levels; and hemophagocytosis in the bone marrow. Clinical and biologic symptoms of hemophagocytic syndrome are caused by cytokines secreted by T-lymphocytes and macrophages. A main challenge in patients with hemophagocytic syndrome is its diagnosis, which must meet well-established criteria (27). The relationship between CCHFV and hemophagocytic syndrome has been previously described (28), but unlike in those studies, the patients in our review did not experience serious bleeding episodes. However, high levels of serum ferritin in patients who underwent analytical determination suggest a higher prevalence of hemophagocytic syndrome than previously described; further research is needed to elucidate the specific mechanisms involved.

All patients received doxycycline accompanied by other antimicrobial drugs, possibly because of initial suspicion of rickettsiosis. Five patients required intensive care treatment; 3 of them died. Ribavirin was prescribed to 3 patients, who all recovered and survived. Despite the potential benefit of ribavirin, the small number of patients makes it difficult to draw conclusions regarding its effectiveness for treating CCHF patients. Furthermore, a recent Cochrane meta-analysis was unable to confirm the potential benefit of ribavirin in CCHFV-infected patients (29).

In Spain, where most CCHF patients have been diagnosed since 2018, the fatality rate of CCHF was as high as 30%. Of note, those 3/10 patients who died showed the highest Bakir-scale scores (>7) at admission. Previous studies have shown that in this viral infection transmitted by ticks, regional differences in mortality rates may be related to factors including the availability of advanced medical care facilities, faster diagnosis because of a better surveillance system that enables early detection of cases with mild to moderate clinical findings, the routes of acquisition of the infection, and the genotype of the virus. In Turkey, which has a CCHF mortality rate of ≈5%, the most common strain is homologous to the strain detected in Russia and Kosovo, whereas in Spain, the most common strain is the Africa III. Two of our cases infected with strain V have had good outcomes described; cases of genotypes III and V have been detected in the same area.

Previous studies indicated that birds are involved in the transmission of the Africa genotype III virus (30). Domestic animals such as pigs have been imported from countries in eastern Europe, indicating a possible relationship with the CCHF epidemiology of European strains, particularly those of genotype V. Of interest, a strain of CCHFV was detected in ticks in Spain (21). From a clinical point of view, genotypes III and IV have been associated with more deaths than genotype V in our cases, although the number of patients still remains very limited.

In Spain, circulation in wild animals of 3 different genotypes (III, IV, and V) of CCHFV has been demonstrated, even in the same geographic area; genotype III was the most prevalent. Those data suggest that the expansion pathways of the different CCHFV genotypes in Spain are complex and coincide over time; further studies are needed to clarify the dissemination of CCHFV in southern Europe. In addition, our results revealed a complex epidemiologic pattern in Spain in which uncommon CCHF cases were associated with high mortality rates. Thus, although the risk is considered low, hospital doctors and general practitioners should be alert to the possibility of new CCHF cases, given the high pathogenicity of CCHFV. A detailed medical history of the patient, including travel history and possible risk factors, is critical for fast diagnosis and appropriate adoption of therapeutic measures for timely control of the infection.

Top

Acknowledgments

We thank all the staff of the Hospitals of Castilla y Leon, Spain, for their extraordinary dedication and contribution to the care of patients with CCHF.

Funding was provided by Consejería de Sanidad, Junta de Castilla y León; Institute of Health Carlos III, Spain; and Red de Investigación Cooperativa en Enfermedades Tropicales (grant nos. RD16/0027/0018 and RD16CIII/0003/0003). European Union co-financing was through Fondo Europeo de Desarrollo Regional (“Una manera de hacer Europa” funding and grant no. IPI16/01784).

Top

References

  1. Ballinger  MJ, Medeiros  AS, Qin  J, Taylor  DJ. Unexpected differences in the population genetics of phasmavirids (Bunyavirales) from subarctic ponds. Virus Evol. 2017;3:vex015. DOIPubMedGoogle Scholar
  2. Dai  S, Deng  F, Wang  H, Ning  Y. Crimean-Congo hemorrhagic fever virus: current advances and future prospects of antiviral strategies. Viruses. 2021;13:1195. DOIPubMedGoogle Scholar
  3. Çevik  MA, Erbay  A, Bodur  H, Gülderen  E, Baştuğ  A, Kubar  A, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis. 2008;12:3749. DOIPubMedGoogle Scholar
  4. Bodur  H, Akinci  E, Ascioglu  S, Öngürü  P, Uyar  Y. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg Infect Dis. 2012;18:6402. DOIPubMedGoogle Scholar
  5. Mostafavi  E, Pourhossein  B, Chinikar  S. Clinical symptoms and laboratory findings supporting early diagnosis of Crimean-Congo hemorrhagic fever in Iran. J Med Virol. 2014;86:118892. DOIPubMedGoogle Scholar
  6. Bente  DA, Forrester  NL, Watts  DM, McAuley  AJ, Whitehouse  CA, Bray  M. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. 2013;100:15989. DOIPubMedGoogle Scholar
  7. Spengler  JR, Bente  DA. Crimean-Congo hemorrhagic fever in Spain—new arrival or silent resident? N Engl J Med. 2017;377:1068. DOIPubMedGoogle Scholar
  8. Estrada-Peña  A, de la Fuente  J. The ecology of ticks and epidemiology of tick-borne viral diseases. Antiviral Res. 2014;108:10428. DOIPubMedGoogle Scholar
  9. Monsalve-Arteaga  L, Alonso-Sardón  M, Muñoz Bellido  JL, Vicente Santiago  MB, Vieira Lista  MC, López Abán  J, et al. Seroprevalence of Crimean-Congo hemorrhagic fever in humans in the World Health Organization European region: A systematic review. PLoS Negl Trop Dis. 2020;14:e0008094. DOIPubMedGoogle Scholar
  10. Negredo  A, de la Calle-Prieto  F, Palencia-Herrejón  E, Mora-Rillo  M, Astray-Mochales  J, Sánchez-Seco  MP, et al.; Crimean Congo Hemorrhagic Fever@Madrid Working Group. Autochthonous Crimean-Congo Hemorrhagic Fever in Spain. N Engl J Med. 2017;377:15461. DOIPubMedGoogle Scholar
  11. Negredo  A, Sánchez-Ledesma  M, Llorente  F, Pérez-Olmeda  M, Belhassen-García  M, González-Calle  D, et al. Retrospective identification of early autochthonous case of Crimean-Congo hemorrhagic fever, Spain, 2013. Emerg Infect Dis. 2021;27:17546. DOIPubMedGoogle Scholar
  12. Negredo  A, Sánchez-Arroyo  R, Díez-Fuertes  F, de Ory  F, Budiño  MA, Vázquez  A, et al. Fatal case of Crimean-Congo hemorrhagic fever caused by reassortant virus, Spain, 2018. Emerg Infect Dis. 2021;27:12115. DOIPubMedGoogle Scholar
  13. Monsalve Arteaga  L, Muñoz Bellido  JL, Negredo  AI, García Criado  J, Vieira Lista  MC, Sánchez Serrano  , et al. New circulation of genotype V of Crimean-Congo haemorrhagic fever virus in humans from Spain. PLoS Negl Trop Dis. 2021;15:e0009197. DOIPubMedGoogle Scholar
  14. Carroll  SA, Bird  BH, Rollin  PE, Nichol  ST. Ancient common ancestry of Crimean-Congo hemorrhagic fever virus. Mol Phylogenet Evol. 2010;55:110310. DOIPubMedGoogle Scholar
  15. Chamberlain  J, Cook  N, Lloyd  G, Mioulet  V, Tolley  H, Hewson  R. Co-evolutionary patterns of variation in small and large RNA segments of Crimean-Congo hemorrhagic fever virus. J Gen Virol. 2005;86:333741. DOIPubMedGoogle Scholar
  16. Bakır  M, Gözel  MG, Köksal  I, Aşık  Z, Günal  Ö, Yılmaz  H, et al. Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis. 2015;34:32530. DOIPubMedGoogle Scholar
  17. Estrada-Peña  A, Palomar  AM, Santibáñez  P, Sánchez  N, Habela  MA, Portillo  A, et al. Crimean-Congo hemorrhagic fever virus in ticks, Southwestern Europe, 2010. Emerg Infect Dis. 2012;18:17980. DOIPubMedGoogle Scholar
  18. Monsalve Arteaga  L, Muñoz Bellido  JL, Vieira Lista  MC, Vicente Santiago  MB, Fernández Soto  P, Bas  I, et al. Crimean-Congo haemorrhagic fever (CCHF) virus-specific antibody detection in blood donors, Castile-León, Spain, summer 2017 and 2018. Euro Surveill. 2020;25:1900507. DOIPubMedGoogle Scholar
  19. Moraga-Fernández  A, Ruiz-Fons  F, Habela  MA, Royo-Hernández  L, Calero-Bernal  R, Gortazar  C, et al. Detection of new Crimean-Congo haemorrhagic fever virus genotypes in ticks feeding on deer and wild boar, Spain. Transbound Emerg Dis. 2021;68:9931000. DOIPubMedGoogle Scholar
  20. Espunyes  J, Cabezón  O, Pailler-García  L, Dias-Alves  A, Lobato-Bailón  L, Marco  I, et al. Hotspot of Crimean-Congo hemorrhagic fever virus seropositivity in wildlife, northeastern Spain. Emerg Infect Dis. 2021;27:24804. DOIPubMedGoogle Scholar
  21. Sánchez-Seco  MP, Sierra  MJ, Estrada-Peña  A, Valcárcel  F, Molina  R, de Arellano  ER, et al.; Group for CCHFv Research. Widespread detection of multiple strains of Crimean-Congo hemorrhagic fever virus in ticks, Spain. Emerg Infect Dis. 2021;28:394402. DOIPubMedGoogle Scholar
  22. Negredo  A, Habela  , Ramírez de Arellano  E, Diez  F, Lasala  F, López  P, et al. Survey of Crimean-Congo hemorrhagic fever enzootic focus, Spain, 2011–2015. Emerg Infect Dis. 2019;25:117784. DOIPubMedGoogle Scholar
  23. Papa  A, Sidira  P, Larichev  V, Gavrilova  L, Kuzmina  K, Mousavi-Jazi  M, et al. Crimean-Congo hemorrhagic fever virus, Greece. Emerg Infect Dis. 2014;20:28890. DOIPubMedGoogle Scholar
  24. Ahmeti  S, Berisha  L, Halili  B, Ahmeti  F, von Possel  R, Thomé-Bolduan  C, et al. Crimean-Congo hemorrhagic fever, Kosovo, 2013–2016. Emerg Infect Dis. 2019;25:3214. DOIPubMedGoogle Scholar
  25. Yilmaz  GR, Buzgan  T, Irmak  H, Safran  A, Uzun  R, Cevik  MA, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis. 2009;13:3806. DOIPubMedGoogle Scholar
  26. Aker  S, Akıncı  H, Kılıçoğlu  C, Leblebicioglu  H. The geographic distribution of cases of Crimean-Congo hemorrhagic fever: Kastamonu, Turkey. Ticks Tick Borne Dis. 2015;6:7306. DOIPubMedGoogle Scholar
  27. Henter  JI, Horne  A, Aricó  M, Egeler  RM, Filipovich  AH, Imashuku  S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:12431. DOIPubMedGoogle Scholar
  28. Tasdelen Fisgin  N, Fisgin  T, Tanyel  E, Doganci  L, Tulek  N, Guler  N, et al. Crimean-Congo hemorrhagic fever: five patients with hemophagocytic syndrome. Am J Hematol. 2008;83:736. DOIPubMedGoogle Scholar
  29. Johnson  S, Henschke  N, Maayan  N, Mills  I, Buckley  BS, Kakourou  A, et al. Ribavirin for treating Crimean Congo haemorrhagic fever. Cochrane Database Syst Rev. 2018;6:CD012713. DOIPubMedGoogle Scholar
  30. Palomar  AM, Portillo  A, Santibáñez  P, Mazuelas  D, Arizaga  J, Crespo  A, et al. Crimean-Congo hemorrhagic fever virus in ticks from migratory birds, Morocco. Emerg Infect Dis. 2013;19:2603. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to https://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title: 
Crimean-Congo Hemorrhagic Fever, Spain, 2013–2021
CME Questions
  • Which one of the following statements regarding Crimean-Congo hemorrhagic fever (CCHF) is most accurate?

    • It is caused by a single-stranded RNA virus of the genus Orthonairovirus

    • It invariably causes severe illness

    • It often promotes leukocytosis and thrombocytosis

    • Its distribution is limited to Africa and southern Europe

  • Which one of the following statements regarding the epidemiology of CCHF in the current study is most accurate?

    • The mean age of patients was 17 years

    • All cases occurred in spring and summer

    • 90% of cases occurred in rural areas

    • No patient reported tick bites

  • Which one of the following statements regarding the clinical presentation and outcomes of CCHF in the current study is most accurate?

    • The median duration between tick bites and symptoms was 9 days

    • All patients presented with fever and exanthems

    • Bleeding occurred in 2 patients

    • The mortality rate was 70%

  • Which one of the following genotypes was most common in the current study?

    • I

    • II

    • III

    • IV

Top

Cite This Article

DOI: 10.3201/eid2902.220677

Original Publication Date: January 23, 2023

1These authors contributed equally to this article.

Related Links

Table of Contents – Volume 29, Number 2—February 2023

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Moncef Belhassen-García, Servicio de Medicina Interna, Unidad de Infecciosas. Universidad de Salamanca, Paseo San Vicente 58 Salamanca, Salamanca 37007, Spain

Send To

10000 character(s) remaining.

Top

Page created: January 23, 2023
Page updated: January 23, 2023
Page reviewed: January 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external